ILC2 Cell Therapy for GVHD Control While Preserving GVL
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for Graft-Versus-Host Disease (GVHD) following hematopoietic stem cell transplant (HSCT) are inadequate, with up to 80% of patients developing acute GVHD and less than one-third surviving past a year despite systemic steroid therapy, and cell-based therapies like Tregs, MSCs, and MDSCs showing only modest success.
Innovation Solution
Utilizing IL-10-producing innate lymphoid cells (ILC2s) to suppress allogeneic T cell responses by expanding them ex vivo and administering them to patients, which are shown to reduce GVHD severity and prolong survival in xenograft models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic steroid therapy is used to treat acute GVHD, then some patients experience symptom relief, but less than one-third of non-responders survive past one year
Solution Approach 1:
The patent uses IL-10 as an intermediary molecule to mediate between the immune system components. IL-10-producing ILCs act as mediators that suppress harmful T cell responses while preserving protective immune functions, providing a more effective treatment mechanism than direct steroid administration.
Solution Approach 2:
The patent converts the harmful overactive immune response into a beneficial controlled response by using IL-10 to suppress pathogenic T cells while maintaining the GVL effect. The same immune system that causes GVHD is redirected to fight leukemia through selective suppression of harmful components.
2Reliability
If cell-based therapies using Tregs, MSCs, or MDSCs are administered, then some immunosuppression is achieved, but clinical trial results show only modest success
Solution Approach 1:
The patent changes the biological parameters of the therapy by using IL-10-producing ILCs instead of conventional cell therapies. This parameter change (cell type selection) provides superior immunosuppression while maintaining simpler implementation compared to complex multi-cell therapies.
3Object-affected harmful factors
If immunosuppressive therapy is administered to reduce GVHD, then T cell responses are suppressed, but the Graft-Versus-Leukemia effect may be impaired
Solution Approach 1:
The patent applies local quality by selectively suppressing harmful T cell responses in specific contexts (GVHD) while preserving protective T cell functions (GVL). IL-10 provides targeted immunosuppression that distinguishes between pathogenic and beneficial immune responses based on local tissue context and cytokine environment.
Solution Approach 2:
The patent implements feedback control where IL-10 production responds to immune activation signals and adjusts suppression levels accordingly. The IL-10-producing ILCs sense the immune environment and modulate T cell responses dynamically, providing feedback-based regulation that prevents both GVHD and preserves GVL.
Data Source
AI summary
There is described herein methods of ameliorating, treating or preventing graft-versus-host disease, transplant rejection or an autoimmune disorder, or promoting transplant graft function in a human using innate lymphoid cells (ILCs), including compositions comprising ILCs and methods for making the same.